The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms

World Journal of Urology

Volumn 26, Issue 6, 2008, Pages 603-609

  Kedia, George T ^a   Ückert, Stefan ^a,b   Jonas, Udo ^a   Kuczyk, Markus A ^a   Burchardt, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Urological Research Unit   (Germany)

Author keywords

BPH; Cyclic GMP; LUTS; Nitric oxide (NO); Nitric oxide synthase (NOS); PDE inhibitors; Phosphodiesterase (PDE) isoenzymes; Prostate

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; HUMAN; MALE; METABOLISM; PROSTATE; PROSTATE HYPERTROPHY;

HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROSTATE; PROSTATIC HYPERPLASIA;

EID: 56449099228     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0303-y     Document Type: Article

References (52)

1. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142
2. Andersson KE, Persson K (1994) Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles. World J Urol 12:274-280
3. Andersson KE (2001) Pharmacology of penile erection. Pharmacol Rev 53:417-450
4. Andersson KE, Persson K (1995) Nitric oxide synthase and the lower urinary tract: Possible implications for physiology and pathophysiology. Scand J Urol Nephrol 175(Suppl):43-53
5. Hedlund P (2005) Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - is there a basis for pharmacological targeting of cGMP? World J Urol 23:362-367
6. Andersson KE (2007) LUTS treatment: Future treatment options. Neurourol Urodyn 26:928-933
7. Förstermann U, Closs EI, Pollack JS, Nakane M, Schwarz P, Gath I, Kleinert H (1994) Nitric oxide synthase isoenzymes: Characterization, purification, molecular cloning and functions. Hypertension 23:1112-1131
8. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP (2000) Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 184:409-420
9. Ückert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG (2006) Update on phosphodiesterase (PDE) isoenzymes as pharmacological targets in urology: Present and future. Eur Urol 50:1194-1207
10. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TSK (1995) Characterization and localization of nitric oxide synthase in the human prostate. Urology 45:435-439
11. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33:1-8
12. Sjöstrand NO, Ehren I, Eldh J, Wiklund NP (1998) NADPH-diaphorase in glandular cells and nerves and its relation to acetylcholinesterase-positive nerves in the male reproductive tract of man and guinea-pig. Urol Res 26:181-188
13. Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE (1997) Heme oxygenase and NO-synthase in the human prostate - relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63:115-126
14. Richter K, Heuer O, Ückert S, Stief CG, Jonas U, Wolf G (2004) Immunocytochemical distribution of nitric oxide synthases in the human prostate. J Urol 171(Suppl 4):347 (abstract)
15. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, di Silverio F, Russo MA (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224-229
16. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, Isaacs W (2002) Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51:189-200
17. Aikawa K, Yokota T, Okamura H, Yamaguchi O (2001) Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: The changes with aging. Prostate 48:40-46
18. Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897-1903
19. Baltaci S, Orhan D, Gügüs C, Türkölmez K, Tulunay Ö, Gügüs O (2001) Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 88:100-103
20. Vaandrager AB, de Jonge HR (1996) Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 157:23-30
21. Haynes JM, Cook ALM (2006) Protein kinase G-induced activation of K ATP channels reduces contractility of human prostate tissue. Prostate 66:377-385
22. Waldkirch ES, Ückert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P (2007) Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 52:495-502
23. Ückert S, Küthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484-2490
24. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49:740-745
25. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H (1995) Effects of nitric oxide on human and canine prostates. Urology 45:440-446
26. Kedia G, Ückert S, Scheller F, Chigogidze T, Managadze L, Jonas U, Truss MC (2006) In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 67:1292-1297
27. Kedia G, Ückert S, Kedia M, Truss MC, Chigogidze T, Jonas U, Managadze L (2006) In vitro effects of drugs interfering with the cAMP- and cGMP-pathway on the tension induced by endothelin-1 of isolated human prostate tissue. Georgian Med News 131:7-13
28. Ückert S, Sormes M, Kedia G, Gratzke C, Stief CG, Scheller F, Jonas U (2006) Effects of PDE inhibitors on the tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostate tissue. Urologe 45(Suppl 1):25-26 (abstract) 25-26
29. Kedia G, Sormes M, Ückert S, Scheller F, Jonas U (2007) Contraction-relaxation studies on isolated human prostate tissue: The role of endothelin 1, phosphodiesterase inhibitors and cyclic nucleotides. Eur Urol 6(Suppl 2):34 (Abstract)
30. Stief CG, Ückert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U (2000) Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 55:146-150
31. Friebe A, Müllershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced GMP effects in human platelets. Mol Pharmacol 54:962-967
32. Müllershausen F, Russwurm M, Friebe A, Koesling D (2004) Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109:1711-1713
33. Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U (1999) Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31:335-341
34. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836-839
35. Mulhall JP, Guhring P, Parker M, Hopps C (2006) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3:662-667
36. Ying J, Yao D, Jiang Y, Ren X, Xu M (2004) The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 10:681-683
37. Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717-1723
38. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 177:1071-1077
39. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401-1407
40. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 53:1236-1244
41. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P (2006) Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98:1259-1263
42. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vanneli GB, Carini M, Forti G, Maggi M (2007) Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 148:1019-1029
43. Yono M, Yamamoto Y, Yoshida M, Ueda S, Latifpour J (2007) Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci 81:218-222
44. Pinggera GM, Schuster A, Frauscher F, Bartsch G, Strasser H (2004) Sildenafil citrate causes a 3-fold increase in periurethral prostatic blood flow. J Urol 171(Suppl 4):355 (abstract)
45. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM (1998) Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53:467-474
46. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP (2002) Lysophosphatidic acid stimulates proliferation of cultured muscle cells from human BPH tissue: Sildenafil and papaverine generate inhibition. Prostate 51:50-58
47. Deng CH, Chen HR, Qiu SP, Liu JZ, Zheng KL, Mei H (2004) Effect of nitric oxide donor and alpha 1 -receptor antagonist on proliferation/ apoptosis of hyperplastic prostatic stromal cells in vitro. Zhonghua Wai Ke Za Zhi 42:201-204
48. Reynard JM, Yang Q, Donovan JL, Peters TJ, Schäfer W, de la Rosette JJ, Dabhoiwala NF, Osawa D, Lim AT, Abrams P (1998) The ICS-BPH study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 82:619-623
49. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol (Epub ahead of print)
50. Shapiro E, Hartanto V, Lepor H (1992) The response to alpha-blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21:297-307
51. Ückert S, Mayer ME, Stief CG, Jonas U (2007) The future of the oral pharmacotherapy of male erectile dysfunction - things to come. Expert Opin Emerg Drugs 12:219-228
52. de Nucci G, Lorenzetti R, Okuyama CE, Baracat JS, Donato JL, Antunes E, Teixeira CE (2007) Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Urology 70(Suppl 3A):105 (abstract)